Evidence map›Paper›PMID 22431191›Full record

ArticleThe Journal of pathology2012

What drives breast cancer heterogeneity: oncogenic events or cell of origin?

Christophe Ginestier, Emmanuelle Charafe-Jauffret, Daniel Birnbaum

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Christophe GinestierCentre de Recherche en Cancerologie de Marseille (CRCM), Laboratoire d'Oncologie Moléculaire, Marseille, France.
Emmanuelle Charafe-Jauffret
Daniel Birnbaum

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is known to show considerable inter-tumoural heterogeneity. It is widely accepted that combinations of oncogenic events have a major role in determining tumour phenotype. However, accumulating evidence suggests that the identity of the cell that acquires the first oncogenic event, the so-called cell of origin, may define the molecular subtype of the resulting tumour. Recent work published in the Journal of Pathology by Natrajan and colleagues questions the origin of breast cancer heterogeneity. After studying BRCA1 tumours, they suggest that genomic alterations are not sufficient to determine tumour behaviour. These and other recent observations underscore the importance of defining what is causing tumour heterogeneity, so that appropriate therapy can be given.

Indexed as

Germ-Line MutationBRCA1 ProteinBreast NeoplasmsCarcinoma, Ductal, BreastFemaleHumansReceptors, EstrogenBRCA1 ProteinReceptors, Estrogen

Identifiers

PMID22431191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.